Mission /vision

The International Consortium on Anti-Virals (ICAV) was founded to discover and develop anti-viral therapies for neglected and emerging diseases and to ensure their accessibility to all those in need. ICAV is currently developing therapies for viral diseases such as avian influenza, HIV/AIDS, hepatitis, Dengue fever, Lassa fever, yellow fever, chikungunya, hemorrhagic fevers such as Ebola and Marburg, and other infectious viral diseases.

Vision

Global access to affordable anti-viral therapies for neglected and emerging viral diseases.

Mission

Through the international collaboration of scientists, governments and industry, ICAV accelerates the discovery and development of novel anti-viral therapies. ICAV will ensure the delivery of these therapies to those most in need.

Objective

The delivery of one novel anti-viral drug to market every five years.

Why ICAV is Needed

Millions of people die from viral diseases every year. Most of those affected cannot afford therapies.
The global community is unequipped to deal with the next pandemic.
Pharmaceutical companies have failed to fill the anti-viral gap.
ICAV is accelerating the development of novel, effective and accessible anti-viral therapies.
ICAV will ensure that its therapies are available at cost or for free in lower- and middle-income countries.
ICAV is developing therapies that will provide the first line of defence in the next pandemic situation.